Last updated: September 5, 2026
Sotatercept-csrk, marketed by Merck as Winrevair, is one of the highest-value launches in pulmonary arterial hypertension. FDA approval on March 26, 2024, created the first commercially available activin-signaling pathway therapy for PAH. Its clinical differentiation, subcutaneous dosing, and use across intermediate- and high-risk patients support a multibillion-dollar opportunity. The principal risks are reimbursement friction, specialist-center adoption, manufacturing scale-up, competing PAH combinations, and eventual biosimilar entry after U.S. biologic exclusivity expires in 2036.
What is sotatercept-csrk and how does Winrevair work?
Sotatercept-csrk is a recombinant fusion protein consisting of the extracellular domain of human activin receptor type IIA linked to the Fc domain of human IgG1. It binds selected transforming growth factor-beta superfamily ligands and is designed to rebalance pro-proliferative and anti-proliferative signaling in the pulmonary vasculature.
The FDA approved Winrevair for adults with pulmonary arterial hypertension, WHO Group 1, to increase exercise capacity and improve functional status. The labeled starting dose is 0.3 mg/kg by subcutaneous injection, followed by a target dose of 0.7 mg/kg every three weeks.[1]
The drug was developed by Acceleron Pharma and became part of Merck’s portfolio through Merck’s acquisition of Acceleron for approximately $11.5 billion in 2021.[2]
What clinical evidence supports the commercial opportunity?
The STELLAR Phase 3 trial enrolled patients receiving background PAH therapy. Sotatercept produced a statistically significant improvement in six-minute walk distance and improved multiple secondary measures, including time to clinical worsening, pulmonary vascular resistance, NT-proBNP, and WHO functional class.[3]
The commercial implication is important: Winrevair is positioned as an add-on therapy rather than a replacement for endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin therapies, or soluble guanylate cyclase stimulators. It can therefore expand total treatment value per patient.
How large is the sotatercept-csrk market opportunity?
Analysts generally place peak annual Winrevair sales in the multibillion-dollar range, although forecasts differ based on penetration, treatment duration, geographic access, and pricing. The addressable population is smaller than the total PAH population because diagnosis is concentrated in specialty centers and not every patient will qualify for, tolerate, or receive advanced therapy.
| Market driver |
Commercial effect |
| U.S. PAH prevalence |
Establishes the initial high-value market |
| Add-on positioning |
Increases revenue per treated patient |
| Every-three-week dosing |
Supports chronic recurring revenue |
| Specialist distribution |
Concentrates prescribing among experienced centers |
| Risk reduction and functional improvement |
Supports payer and physician adoption |
| Injectable administration |
Creates training, storage, and adherence requirements |
| Global expansion |
Adds Europe, Japan, and other regulated markets |
| New indications |
Could materially expand the addressable population |
Merck has not disclosed a separate long-term revenue forecast for Winrevair in its public filings. External estimates have commonly placed peak sales between approximately $3 billion and $5 billion annually, depending on assumptions about market share and label expansion. Those estimates should be treated as commercial scenarios rather than company guidance.
What were the early financial results for Winrevair?
Winrevair generated its first commercial revenue in 2024 after the March FDA approval. Merck reported approximately $148 million in first-quarter 2024 sales, reflecting a partial launch period.[4] The result was strong for a product available for only a portion of the quarter and indicated rapid uptake among U.S. PAH treatment centers.
The financial trajectory has four phases:
| Phase |
Timing |
Financial profile |
| Prelaunch development |
Through 2023 |
No commercial Winrevair revenue; high R&D and regulatory spending |
| Initial launch |
2024 |
Rapid U.S. adoption, launch inventory, access-building costs |
| International expansion |
2025-2027 |
Broader reimbursement and specialist-center penetration |
| Mature growth |
2028 onward |
Geographic expansion, label expansion, and deeper use in combination therapy |
The first-year revenue curve is likely to be constrained by prior authorization, infusion-center and specialty-pharmacy workflows, laboratory monitoring, and the need to identify suitable patients. The product's three-week dosing schedule creates recurring revenue, but initiation can be slower than for oral agents because of injection training and hematologic monitoring.
When does sotatercept-csrk lose exclusivity?
U.S. regulatory exclusivity for Winrevair is expected to run for 12 years from the March 26, 2024, approval date, subject to statutory adjustments. That places the reference biologic exclusivity endpoint in March 2036.[5]
Patent expiry dates may extend beyond or fall before regulatory exclusivity, depending on the patent family, patent-term adjustment, patent-term extension, continuation practice, and claim scope. The commercial loss-of-exclusivity date cannot be determined from the FDA approval date alone.
| Protection type |
Expected significance |
| U.S. biologic reference-product exclusivity |
Blocks FDA approval of a biosimilar for 12 years from approval |
| Composition and protein-engineering patents |
Protect the molecule and related binding proteins |
| Formulation patents |
May protect concentration, stability, excipients, or storage |
| Manufacturing patents |
May protect cell culture, purification, or process controls |
| Method-of-use patents |
May cover PAH treatment, dosing, or patient subgroups |
| Foreign patents |
Create country-specific entry dates and litigation exposure |
Because sotatercept is a biologic, it does not follow the small-molecule Hatch-Waxman framework. Generic manufacturers cannot file a conventional Paragraph IV ANDA challenge against Winrevair. A follow-on competitor would generally pursue a biosimilar application under the Public Health Service Act.
What is the Orange Book and Purple Book status of Winrevair?
Winrevair is not an Orange Book-listed small-molecule drug. Biologic reference products are tracked through the FDA Purple Book framework rather than the Orange Book.[6]
The distinction affects competition:
- No conventional ANDA pathway exists for sotatercept-csrk.
- No standard Paragraph IV certification applies.
- Biosimilar applicants must provide analytical, pharmacokinetic, immunogenicity, and, where required, clinical evidence.
- The biologics patent-dispute process includes a separate notice and exchange framework under the Biologics Price Competition and Innovation Act.
- A biosimilar may be approved before all listed or asserted patents expire, but commercial launch depends on patent settlements, injunctions, licenses, or litigation outcomes.
Which patents protect sotatercept-csrk?
The sotatercept patent estate is expected to include patents covering the fusion protein, related ActRIIA-binding proteins, pharmaceutical compositions, therapeutic uses, dosing regimens, and manufacturing methods. Public patent databases identify multiple Acceleron- and Merck-associated patent families, but the relevant protection must be assessed patent by patent because expiration dates and enforceability differ.
The most commercially important claims are likely to be:
Composition patents
Composition claims can cover the amino-acid sequence, Fc-fusion architecture, binding characteristics, and defined variants. These claims generally provide the strongest direct barrier because a biosimilar must use a highly similar molecule.
Formulation patents
Formulation claims may cover concentration, pH, excipient combinations, aggregation control, vial or cartridge presentations, and storage conditions. Formulation patents may delay an exact commercial substitute even if composition claims are challenged.
Method-of-use patents
Method patents may cover treatment of PAH, improvement of pulmonary vascular resistance, reduction of clinical worsening, or administration to defined risk groups. Their value depends on claim breadth and whether physicians, payers, or manufacturers can be held liable for induced infringement.
Manufacturing patents
Manufacturing claims may cover expression systems, purification steps, chromatography, viral clearance, and product-quality controls. These patents can increase development costs for biosimilar competitors, although process patents do not necessarily prevent a non-infringing alternative process.
How strong is the Winrevair patent estate?
The estate is commercially strong for three reasons. First, the product has 12 years of U.S. biologic exclusivity independent of patent enforcement. Second, a complex fusion protein is more difficult to replicate than a conventional tablet. Third, the development platform may support multiple patent categories rather than a single composition patent.
The main weaknesses are timing and claim vulnerability. Core composition patents may expire before regulatory exclusivity. Method-of-use patents can face enforceability challenges, particularly where the claimed treatment overlaps standard PAH practice. Manufacturing claims can often be designed around. Patent strength therefore depends on the specific patent family, not on the number of granted patents alone.
No widely reported Paragraph IV challenge applies because Winrevair is regulated as a biologic rather than a small molecule. No major public biosimilar litigation involving sotatercept-csrk had been established in the initial post-approval period.
What competitors challenge Winrevair?
Winrevair competes within a PAH treatment architecture rather than against one direct substitute. Key commercial competitors include:
| Product or class |
Company |
Competitive position |
| Tracleer and generic bosentan |
J&J and generics |
Established endothelin receptor antagonist, lower-cost option |
| Letairis and generic ambrisentan |
Gilead and generics |
Common background therapy |
| Opsumit |
Johnson & Johnson |
Branded endothelin receptor antagonist |
| Adcirca and generic tadalafil |
Eli Lilly and generics |
Oral PDE-5 inhibitor |
| Revatio and generic sildenafil |
Pfizer and generics |
Oral PDE-5 inhibitor |
| Uptravi |
Johnson & Johnson |
Oral prostacyclin-pathway therapy |
| Remodulin |
United Therapeutics |
Parenteral prostacyclin |
| Tyvaso |
United Therapeutics |
Inhaled treprostinil |
| Yutrepia |
Liquidia Technologies |
Inhaled treprostinil competitor, subject to regulatory and litigation developments |
Winrevair can benefit from widespread use of these products because many patients will receive it in combination. The competitive threat is therefore less likely to be immediate displacement and more likely to involve payer sequencing, treatment-line restrictions, and competing drugs that improve outcomes in similar high-risk patients.
What FDA regulatory milestones and label expansions matter?
The central FDA milestone was approval on March 26, 2024, based largely on STELLAR.[1] Merck is also evaluating sotatercept in broader disease settings and earlier treatment lines. Expansion into newly diagnosed patients, lower-risk patients, or related pulmonary hypertension populations could materially increase sales.
Potential regulatory value drivers include:
- Earlier use in the treatment algorithm.
- Reduction in hospitalization or disease progression.
- Use in patients with more severe disease.
- Pediatric or adolescent indications.
- Applications beyond Group 1 PAH, if supported by clinical data.
Label expansion carries execution risk. Broader populations require additional trials, and safety monitoring remains relevant because sotatercept can cause erythrocytosis, thrombocytopenia, bleeding concerns, and telangiectasia-related events.
What generic launch and biosimilar risks exist?
The first credible U.S. biosimilar launch risk is more likely to arise in the mid-2030s than during the current commercial ramp. The principal barriers are:
- Reference-product exclusivity through approximately March 2036.
- Complex analytical comparability requirements.
- Immunogenicity assessment.
- Specialized manufacturing capacity.
- Limited size of the PAH market relative to mass-market biologics.
- Potential composition, formulation, use, and manufacturing patents.
- Merck’s ability to negotiate settlements or pursue patent litigation.
A biosimilar could still enter selectively through a license or after resolving only the patents relevant to its product design. International entry dates may differ because regulatory exclusivity and patent rights vary by jurisdiction.
What licensing deals affect sotatercept-csrk?
The central transaction was Merck’s acquisition of Acceleron in 2021. The deal transferred sotatercept and Acceleron’s broader pipeline to Merck and established Merck as the global commercial owner.[2]
No major third-party licensing agreement has been necessary to establish Winrevair’s commercial rights in the United States. The acquisition structure gives Merck control over development, manufacturing, regulatory strategy, pricing, and lifecycle management.
What litigation affects Winrevair?
The most important litigation risk is prospective biosimilar and patent litigation, not Paragraph IV litigation. A future biosimilar dispute could involve:
- Patent-listing and disclosure issues.
- Validity of composition claims.
- Infringement of formulation or dosing patents.
- Patent-term adjustment calculations.
- Manufacturing-process claims.
- Launch timing after a settlement.
The absence of a conventional ANDA pathway makes early generic litigation less likely than for a branded small molecule. Merck’s litigation exposure will increase as biosimilar developers approach commercial filing and as the remaining patent term narrows.
How does Winrevair compare with competing PAH drugs?
Winrevair has a differentiated mechanism and robust Phase 3 outcome data, while most established PAH products target endothelin, nitric oxide, or prostacyclin pathways. Its main commercial advantage is the potential to modify disease biology beyond vasodilation.
Its disadvantages are the subcutaneous administration, laboratory monitoring, higher expected cost than many generic oral therapies, and dependence on specialty prescribers. Oral generics remain strong tools for initial therapy and payer control. Winrevair is most likely to gain share in patients with inadequate control on background treatment rather than replace low-cost first-line therapy.
What is the revenue exposure for Merck?
Winrevair is strategically important because Merck’s oncology franchise, particularly Keytruda, faces long-term loss-of-exclusivity pressure. A successful PAH launch provides diversification and can contribute recurring revenue before Keytruda’s major patent expiry period.
The financial exposure is asymmetric:
- If adoption is limited to high-risk patients, sales may remain below the highest analyst forecasts.
- If the drug moves earlier in treatment and demonstrates durable clinical benefit, peak sales could reach several billion dollars.
- Manufacturing constraints or payer controls could delay the revenue ramp.
- Safety signals or disappointing long-term outcomes would reduce penetration and valuation support.
- Expansion into additional patient groups would improve the asset’s net present value.
Key Takeaways
- Sotatercept-csrk is marketed as Winrevair and was FDA-approved on March 26, 2024.
- Merck acquired the asset through its approximately $11.5 billion acquisition of Acceleron.
- Winrevair is an add-on biologic for PAH, with a three-week subcutaneous dosing schedule.
- Merck reported approximately $148 million in first-quarter 2024 Winrevair sales after a partial launch.
- External peak-sales estimates generally fall in the $3 billion-to-$5 billion range.
- U.S. biologic exclusivity is expected to extend to approximately March 2036.
- Winrevair is governed by the Purple Book framework, not the Orange Book, and is not subject to conventional Paragraph IV ANDA litigation.
- The patent estate likely includes composition, formulation, method-of-use, and manufacturing claims.
- The strongest competitive threat is payer sequencing and established combination therapy, not immediate generic substitution.
- The main long-term risk is biosimilar entry after regulatory exclusivity and relevant patent protection expire.
Frequently Asked Questions
Is sotatercept-csrk a biologic or a small-molecule drug?
Sotatercept-csrk is a biologic fusion protein. It is regulated under the Public Health Service Act and competes with biosimilars rather than conventional ANDA generics.
What is the brand name for sotatercept-csrk?
The brand name is Winrevair. Merck commercializes the product globally.
Can a generic manufacturer file a Paragraph IV challenge against Winrevair?
No. Paragraph IV certifications apply to small-molecule products under the Hatch-Waxman Act. A competing sotatercept product would generally follow the biosimilar pathway.
How often is Winrevair administered?
The target dose is administered by subcutaneous injection once every three weeks, following a lower initial dose.
What could expand the Winrevair market beyond current PAH use?
Earlier-line treatment, broader risk categories, improved long-term outcome data, pediatric approval, and new pulmonary hypertension indications could expand the addressable market.
References
- U.S. Food and Drug Administration. (2024, March 26). FDA approves drug to treat pulmonary arterial hypertension. https://www.fda.gov
- Merck & Co., Inc. (2021, September 30). Merck to acquire Acceleron Pharma Inc. https://www.merck.com
- Hoeper, M. M., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg-Maitland, M., McLaughlin, V. V., Preston, I. R., Souza, R., Waxman, A. B., & Meyer, G. (2023). Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. New England Journal of Medicine, 388(16), 1478-1490.
- Merck & Co., Inc. (2024). First-quarter 2024 results. https://www.merck.com
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
